Activity of isatine-sulfadimidine derivatives against 2009 pandemic H1N1 influenza virus in cell culture
- PMID: 20054101
- DOI: 10.3851/IMP1471
Activity of isatine-sulfadimidine derivatives against 2009 pandemic H1N1 influenza virus in cell culture
Abstract
Background: The development of antiviral drugs has provided crucial new means to mitigate or relieve the debilitating effects of many viral pathogens. New classes of inhibitors are essential to combat swine influenza viral infection.
Methods: A series of isatine-sulfadimidine derivatives were screened for antiviral activity against swine influenza A/California/07/2009 (H1N1) virus in Madin-Darby canine kidney (MDCK) cell culture. Cytotoxicity of the synthesized compounds was also tested in uninfected MDCK cells.
Results: All the compounds inhibit the influenza A (H1N1) in MDCK cells. The most active compounds, SPIII-5Br and SPIII-5H, inhibited virus-induced cytopathology by 50% at 27 and 30 microM, respectively, with 50% cytotoxicity occurring at a much higher dose (975-1,000 microM). The positive control compound ribavirin inhibits the replication of the virus at 18 microM and cytotoxic concentration was found to be >1,000 microM.
Conclusions: SPIII-5Br and SPIII-5H exhibited potency in the same range as ribavirin and are suitable candidate molecules for further investigation.
Similar articles
-
Anti-influenza virus activities of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N-(4,6-dimethyl-2-pyrimidin-2-yl)benzenesulphonamide and its derivatives.Antivir Chem Chemother. 2006;17(5):269-74. doi: 10.1177/095632020601700504. Antivir Chem Chemother. 2006. PMID: 17176631
-
Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses.J Clin Virol. 2009 Dec;46(4):325-30. doi: 10.1016/j.jcv.2009.09.013. Epub 2009 Oct 3. J Clin Virol. 2009. PMID: 19801200
-
Anti-influenza A virus activity of uridine derivatives of 2-deoxy sugars.Antiviral Res. 2013 Oct;100(1):90-7. doi: 10.1016/j.antiviral.2013.07.014. Epub 2013 Aug 1. Antiviral Res. 2013. PMID: 23911991
-
Inhibitors of influenza viruses replication: a patent evaluation (WO2013019828).Expert Opin Ther Pat. 2013 Nov;23(11):1517-24. doi: 10.1517/13543776.2013.831073. Epub 2013 Aug 23. Expert Opin Ther Pat. 2013. PMID: 23967861 Review.
-
Flavonoids in the therapy and prophylaxis of flu: a patent review.Expert Opin Ther Pat. 2012 Oct;22(10):1111-21. doi: 10.1517/13543776.2012.724062. Epub 2012 Sep 13. Expert Opin Ther Pat. 2012. PMID: 22971104 Review.
Cited by
-
A survey of isatin hybrids and their biological properties.Mol Divers. 2025 Apr;29(2):1737-1760. doi: 10.1007/s11030-024-10883-z. Epub 2024 Jun 4. Mol Divers. 2025. PMID: 38833124 Free PMC article. Review.
-
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.Antiviral Res. 2012 Oct;96(1):13-20. doi: 10.1016/j.antiviral.2012.07.002. Epub 2012 Jul 15. Antiviral Res. 2012. PMID: 22809862 Free PMC article.
-
From Structure to Function: Isatin Derivatives as a Promising Class of Antiviral Agents.Curr Drug Targets. 2025;26(7):470-488. doi: 10.2174/0113894501352560250115054156. Curr Drug Targets. 2025. PMID: 39878104 Review.
-
How to approach and treat viral infections in ICU patients.BMC Infect Dis. 2014 Nov 28;14:321. doi: 10.1186/1471-2334-14-321. BMC Infect Dis. 2014. PMID: 25431007 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical